Andrew Komjathy
Chief Commercial Officer · Astria Therapeutics, Inc.
Individual
- 2026
- Jan 23, 2026
- 1
Filings (90d)
Other insiders active in the same sector
No other insider has filed at Andrew Komjathy's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- Brian Taylor Slingsby - $46.36M in MLYS purchases and sales in the last 12 months
- Matthew Gline - $46.17M in ROIV purchases and sales in the last 12 months
- Larry Robbins - $46.04M in BFLY purchases and sales in the last 12 months
- R01 Fund LP - $45.65M in SDEV purchases and sales in the last 12 months
- Michael John Kazley - $45.65M in SDEV purchases and sales in the last 12 months
- Neil Kumar - $45.20M in BBIO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Andrew Komjathy?
Andrew Komjathy is a corporate insider, tracked as Chief Commercial Officer of Astria Therapeutics, Inc. (ATXS). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Andrew Komjathy last file a Form 4?
The only primary Form 4 on record is dated 23 January 2026.
